BCL2 and triple-negative breast carcinoma: For example, PARP inhibitors enlarged the antitumor activity of sacituzumab govitecan in triple-negative breast cancer [44] and BCL-2/XL inhibitors Enhances the cytotoxicity of T-DM1 [45].